Squamous cell carcinoma of the skin - Revision history

Michael: /* IHC */

2022-06-07T16:19:22Z

IHC

← Older revision		Revision as of 16:19, 7 June 2022
Line 125:		Line 125:
	*[[Ber-EP4]] usually -ve.<ref name=pmid19187107>{{Cite journal \| last1 = Yu \| first1 = L. \| last2 = Galan \| first2 = A. \| last3 = McNiff \| first3 = JM. \| title = Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma. \| journal = J Cutan Pathol \| volume = 36 \| issue = 10 \| pages = 1074-176 \| month = Oct \| year = 2009 \| doi = 10.1111/j.1600-0560.2008.01223.x \| PMID = 19187107 }}</ref>		*[[Ber-EP4]] usually -ve.<ref name=pmid19187107>{{Cite journal \| last1 = Yu \| first1 = L. \| last2 = Galan \| first2 = A. \| last3 = McNiff \| first3 = JM. \| title = Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma. \| journal = J Cutan Pathol \| volume = 36 \| issue = 10 \| pages = 1074-176 \| month = Oct \| year = 2009 \| doi = 10.1111/j.1600-0560.2008.01223.x \| PMID = 19187107 }}</ref>
	** Usually +ve in [[BCC]].		** Usually +ve in [[BCC]].
			*EMA +ve (~83% +ve).<ref name=pmid27039776>{{cite journal \|authors=Ramezani M, Mohamadzaheri E, Khazaei S, Najafi F, Vaisi-Raygani A, Rahbar M, Sadeghi M \|title=Comparison of EMA,CEA, CD10 and Bcl-2 Biomarkers by Immunohistochemistry in Squamous Cell Carcinoma and Basal Cell Carcinoma of the Skin \|journal=Asian Pac J Cancer Prev \|volume=17 \|issue=3 \|pages=1379–83 \|date=2016 \|pmid=27039776 \|doi=10.7314/apjcp.2016.17.3.1379 \|url=}}</ref>
			** Usually -ve in BCC.

	==Staging==		==Staging==

Michael at 18:21, 21 September 2020

2020-09-21T18:21:21Z

← Older revision		Revision as of 18:21, 21 September 2020
Line 6:		Line 6:
	\| Micro =		\| Micro =
	\| Subtypes = many see ''[[squamous cell carcinoma]]''		\| Subtypes = many see ''[[squamous cell carcinoma]]''
	\| LMDDx = [[inverted follicular keratosis]], [[Paget disease of the breast]], [[eccrine carcinoma]], [[atypical fibroxanthoma]], [[malignant melanoma]], [[leiomyosarcoma]], [[basal cell carcinoma]] (for ''[[basaloid squamous cell carcinoma]]''), [[porocarcinoma]]		\| LMDDx = [[inverted follicular keratosis]], [[Paget disease of the breast]], [[eccrine carcinoma]], [[atypical fibroxanthoma]], [[malignant melanoma]], [[leiomyosarcoma]], [[basal cell carcinoma]] (for ''[[basaloid squamous cell carcinoma]]''), [[porocarcinoma]], [[pseudoepitheliomatous hyperplasia]]
	\| Stains =		\| Stains =
	\| IHC = CK5/6 +ve, p63 +ve, K903 +ve, [[Ber-EP4]] -ve, S-100 -ve		\| IHC = CK5/6 +ve, p63 +ve, K903 +ve, [[Ber-EP4]] -ve, S-100 -ve

Michael: /* Microscopic */

2020-09-21T18:20:50Z

Microscopic

← Older revision		Revision as of 18:20, 21 September 2020
Line 81:		Line 81:
	*[[Basal cell carcinoma]] for [[basaloid squamous cell carcinoma]].		*[[Basal cell carcinoma]] for [[basaloid squamous cell carcinoma]].
	*[[Porocarcinoma]].		*[[Porocarcinoma]].
			*[[Pseudoepitheliomatous hyperplasia]].

	===Grading===		===Grading===

Michael: +porocarcinoma

2018-08-13T13:04:09Z

+porocarcinoma

← Older revision		Revision as of 13:04, 13 August 2018
Line 6:		Line 6:
	\| Micro =		\| Micro =
	\| Subtypes = many see ''[[squamous cell carcinoma]]''		\| Subtypes = many see ''[[squamous cell carcinoma]]''
	\| LMDDx = [[inverted follicular keratosis]], [[Paget disease of the breast]], [[eccrine carcinoma]], [[atypical fibroxanthoma]], [[malignant melanoma]], [[leiomyosarcoma]], [[basal cell carcinoma]] (for ''[[basaloid squamous cell carcinoma]]'')		\| LMDDx = [[inverted follicular keratosis]], [[Paget disease of the breast]], [[eccrine carcinoma]], [[atypical fibroxanthoma]], [[malignant melanoma]], [[leiomyosarcoma]], [[basal cell carcinoma]] (for ''[[basaloid squamous cell carcinoma]]''), [[porocarcinoma]]
	\| Stains =		\| Stains =
	\| IHC = CK5/6 +ve, p63 +ve, K903 +ve, [[Ber-EP4]] -ve, S-100 -ve		\| IHC = CK5/6 +ve, p63 +ve, K903 +ve, [[Ber-EP4]] -ve, S-100 -ve
Line 80:		Line 80:
	*[[Eccrine carcinoma]].		*[[Eccrine carcinoma]].
	*[[Basal cell carcinoma]] for [[basaloid squamous cell carcinoma]].		*[[Basal cell carcinoma]] for [[basaloid squamous cell carcinoma]].
			*[[Porocarcinoma]].

	===Grading===		===Grading===

Michael: /* Tumour stage */

2017-11-20T14:20:10Z

Tumour stage

← Older revision		Revision as of 14:20, 20 November 2017
Line 136:		Line 136:
	\|-		\|-
	\| T2		\| T2
	\| >2 cm and less than two high-risk factors ''or'' two ~~more~~ more high-risk factors		\| >2 cm and less than two high-risk factors ''or'' two or more high-risk factors
	\| see ''microscopic'' for list of high-risk factors		\| see ''microscopic'' for list of high-risk factors
	\|-		\|-

Michael at 15:36, 23 June 2016

2016-06-23T15:36:59Z

← Older revision		Revision as of 15:36, 23 June 2016
Line 14:		Line 14:
	\| Gross = scaly patch or nodule, +/-ulceration		\| Gross = scaly patch or nodule, +/-ulceration
	\| Grossing =		\| Grossing =
			\| Staging = [[Squamous_cell_carcinoma_of_the_skin#Staging\|squamous cell carcinoma of the skin staging]]
	\| Site = [[skin]] - usu. sun exposed areas		\| Site = [[skin]] - usu. sun exposed areas
	\| Assdx = [[actinic keratosis]], [[solar elastosis]]		\| Assdx = [[actinic keratosis]], [[solar elastosis]]

Michael: /* Tumour stage */

2016-06-23T15:35:15Z

Tumour stage

← Older revision		Revision as of 15:35, 23 June 2016
Line 132:		Line 132:
	\| T1		\| T1
	\| <=2 cm ''and'' less than two high-risk factors		\| <=2 cm ''and'' less than two high-risk factors
	\|		\| see ''microscopic'' for list of high-risk factors
	\|-		\|-
	\| T2		\| T2
	\| >2 cm and less than two high-risk factors ''or'' two more more high-risk factors		\| >2 cm and less than two high-risk factors ''or'' two more more high-risk factors
	\|		\| see ''microscopic'' for list of high-risk factors
	\|-		\|-
	\| T3		\| T3

Michael: /* Sign-out */

2016-06-23T15:34:13Z

Sign-out

← Older revision		Revision as of 15:34, 23 June 2016
Line 122:		Line 122:
	*[[Ber-EP4]] usually -ve.<ref name=pmid19187107>{{Cite journal \| last1 = Yu \| first1 = L. \| last2 = Galan \| first2 = A. \| last3 = McNiff \| first3 = JM. \| title = Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma. \| journal = J Cutan Pathol \| volume = 36 \| issue = 10 \| pages = 1074-176 \| month = Oct \| year = 2009 \| doi = 10.1111/j.1600-0560.2008.01223.x \| PMID = 19187107 }}</ref>		*[[Ber-EP4]] usually -ve.<ref name=pmid19187107>{{Cite journal \| last1 = Yu \| first1 = L. \| last2 = Galan \| first2 = A. \| last3 = McNiff \| first3 = JM. \| title = Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma. \| journal = J Cutan Pathol \| volume = 36 \| issue = 10 \| pages = 1074-176 \| month = Oct \| year = 2009 \| doi = 10.1111/j.1600-0560.2008.01223.x \| PMID = 19187107 }}</ref>
	** Usually +ve in [[BCC]].		** Usually +ve in [[BCC]].

			==Staging==
			===Tumour stage===
			{\| class="wikitable sortable"
			!T stage
			!Criteria
			!Comment
			\|-
			\| T1
			\| <=2 cm ''and'' less than two high-risk factors
			\|
			\|-
			\| T2
			\| >2 cm and less than two high-risk factors ''or'' two more more high-risk factors
			\|
			\|-
			\| T3
			\| tumour into nearby bone - maxilla, mandible, orbit, temporal bone
			\| uncommonly seen by pathology
			\|-
			\| T4
			\| tumour into axial skeleton or appendicular skeleton or perineural invasion of skull base
			\| basically never seen by pathology
			\|}

	==Sign-out==		==Sign-out==

Michael: /* IHC */

2016-05-15T16:26:53Z

IHC

← Older revision		Revision as of 16:26, 15 May 2016
Line 120:		Line 120:

	Others:		Others:
	*[[Ber-EP4]] -ve.		*[[Ber-EP4]] usually -ve.<ref name=pmid19187107>{{Cite journal \| last1 = Yu \| first1 = L. \| last2 = Galan \| first2 = A. \| last3 = McNiff \| first3 = JM. \| title = Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma. \| journal = J Cutan Pathol \| volume = 36 \| issue = 10 \| pages = 1074-176 \| month = Oct \| year = 2009 \| doi = 10.1111/j.1600-0560.2008.01223.x \| PMID = 19187107 }}</ref>
	** Usually +ve in [[BCC]].		** Usually +ve in [[BCC]].

	==Sign-out==		==Sign-out==
	===Invasive SCC - small===		===Invasive SCC - small===

Michael at 16:25, 15 May 2016

2016-05-15T16:25:38Z

← Older revision		Revision as of 16:25, 15 May 2016
Line 8:		Line 8:
	\| LMDDx = [[inverted follicular keratosis]], [[Paget disease of the breast]], [[eccrine carcinoma]], [[atypical fibroxanthoma]], [[malignant melanoma]], [[leiomyosarcoma]], [[basal cell carcinoma]] (for ''[[basaloid squamous cell carcinoma]]'')		\| LMDDx = [[inverted follicular keratosis]], [[Paget disease of the breast]], [[eccrine carcinoma]], [[atypical fibroxanthoma]], [[malignant melanoma]], [[leiomyosarcoma]], [[basal cell carcinoma]] (for ''[[basaloid squamous cell carcinoma]]'')
	\| Stains =		\| Stains =
	\| IHC = CK5/6 +ve, p63 +ve, K903 +ve, Ber-EP4 -ve, S-100 -ve		\| IHC = CK5/6 +ve, p63 +ve, K903 +ve, [[Ber-EP4]] -ve, S-100 -ve
	\| EM =		\| EM =
	\| Molecular =		\| Molecular =
Line 119:		Line 119:
	**Toker cells CK7 +ve.<ref name=pmid19601945>{{Cite journal \| last1 = Nofech-Mozes \| first1 = S. \| last2 = Hanna \| first2 = W. \| title = Toker cells revisited. \| journal = Breast J \| volume = 15 \| issue = 4 \| pages = 394-8 \| month = \| year = \| doi = 10.1111/j.1524-4741.2009.00743.x \| PMID = 19601945 }}</ref>		**Toker cells CK7 +ve.<ref name=pmid19601945>{{Cite journal \| last1 = Nofech-Mozes \| first1 = S. \| last2 = Hanna \| first2 = W. \| title = Toker cells revisited. \| journal = Breast J \| volume = 15 \| issue = 4 \| pages = 394-8 \| month = \| year = \| doi = 10.1111/j.1524-4741.2009.00743.x \| PMID = 19601945 }}</ref>

			Others:
			*[[Ber-EP4]] -ve.
			** Usually +ve in [[BCC]].
	==Sign-out==		==Sign-out==
	===Invasive SCC - small===		===Invasive SCC - small===